Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Welcome, everyone, to the Thursday morning of the 2020 JPMorgan Health Care Conference. My name is Tessa Romero, and I'm one of the biotechnology analysts here at JPMorgan. On behalf of myself and the team, I'm pleased to welcome to the stage Rigel Pharmaceuticals. And presenting on behalf of the company is CEO, Raul Rodriguez. Raul?
Thank you, Tessa, and good morning. Thank you for joining us. Thank you for -- to you and your colleagues at JPMorgan for inviting us again. It's a pleasure to be here and kick off the year in good fashion.
So let me introduce Rigel to you. Some of you don't know us. I'll tell you a little bit more of the story for those of you who do know us. Some important forward-looking statements, you could read these on our website as well. Let me go to the story.
There are 4 main key value drivers for Rigel, and as you see on this slide. And I'll take you through each
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |